Treatment of allosensitized patients receiving allogeneic transplantation
Stefan O. Ciurea(University of California, Irvine), Kai Cao(Beijing Tongren Hospital), Stephen J. Forman(City Of Hope National Medical Center), Monzr M. Al Malki(City of Hope), Richard E. Champlin(The University of Texas MD Anderson Cancer Center), Piyanuch Kongtim(Thammasat University), Fleur M. Aung(The University of Texas MD Anderson Cancer Center), Salman Otoukesh(City Of Hope National Medical Center), Julianne Chen(The University of Texas MD Anderson Cancer Center), Ketevan Gendzekhadze(City Of Hope National Medical Center), Michiko Taniguchi(City of Hope), Gabriela Rondón(The University of Texas MD Anderson Cancer Center), Auayporn Nademanee(City Of Hope National Medical Center), Jun Zou(The University of Texas MD Anderson Cancer Center)
Cited by 66
Related Papers
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
|New England Journal of Medicine|2016|1.8k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.
|Journal of Clinical Oncology|1997|1.3k